Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FzioMed spine gel wins expedited review

This article was originally published in The Gray Sheet

Executive Summary

FzioMed's PMA for its Oxiplex spine surgery gel is accepted for expedited FDA review, the firm announces Oct. 4. The absorbable adhesion barrier is applied to the nerve root during lumbar disc surgery to reduce post-operative pain and other symptoms. According to FzioMed, FDA granted expedited review status because there are no alternative products approved in the United States. Oxiplex, cleared in Europe in 2001, is marketed outside the United States under the brands Oxiplex/SP and MediShield and has been used in more than 80,000 surgeries

You may also be interested in...



FzioMed Oxiplex Anti-Adhesion Gel Not Approvable For Spine Surgery – Panel

FzioMed's Oxiplex/SP anti-adhesion gel for spine surgery is "not approvable" due to its failure to adequately demonstrate a statistically significant treatment benefit in the sponsor's randomized, pivotal trial, according to FDA's Orthopaedic and Rehabilitation Devices Panel

WHO No-Go Not A Swan Song For Remdesivir In India?

The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.

Quick Listen: Scrip’s Five Must-Know Things

Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things. 

UsernamePublicRestriction

Register

LL1134478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel